• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2001 Fiscal Year Final Research Report Summary

A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving graft-versus-leukemia effect of allogeneic bone marrow transplantation

Research Project

Project/Area Number 11670457
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 内科学一般
Research InstitutionJUNTENDO UNIVERSITY

Principal Investigator

MIYAJIMA Hiroaki  Juntendo University, School of Medicine, Research associate, 医学部, 助手 (80209907)

Co-Investigator(Kenkyū-buntansha) OKUMURA Ko  Juntendo University, School of Medicine, Professor, 医学部, 教授 (50009700)
YAGITA Hideo  Juntendo University, School of Medicine, Associate Professor, 医学部, 助教授 (30182306)
HIRANO Takeo  Juntendo University, School of Medicine, Associate Professor, 医学部, 助教授 (10165186)
Project Period (FY) 1999 – 2001
KeywordsGVHD / TNF-α / Fas / FasL / MPI
Research Abstract

We here examined the effect. of a hydroxamic acid-based matrix metalloproteinase inhibitor (KB-R7785), which we previously demonstrated a potent ameliorating effect on acute graft-versus-host disease (GVHD), on graft-versus-leukemia (GVL) effect of allogeneic bone marrow transplantation (BMT), KB-R7785 was administrated into (C57BL/6 x BALB/c) Fl (CBF1) mice, that had been inoculated with IgE-producing B53 hybridoma cells of BALB/c origin as a model tumor, along with or without transplantation of C57BL/6 (B6) bone marrow cells and spleen cells (BMS). Administration of KB-R7785 without BMS significantly prolonged the survival of B53-inoculated CBF1 mice by inhibiting the infiltration of B53 cells into the liver and spleen. Transplantation o fB6 BMS without KB-R7785 resulted in the death of most recipients due to acute GVHD while efficiently eliminating B53 cells. Administration of KB-R7785 along with B6 BMS resulted in 50% survival of B53-inoculated CBF1 mice over 50 days without histological manifestations of acute GVHD or residual B53 cells. These results indicate beneficial effects of KB-R7785 that inhibit tumor infiltration and prevent acute GVHD while preserving the GVL effect of allogeneic BMT.

  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] Nozawa, K.: "Preferential blocade of CD8+T cell responses by administration of anti-CD137 ligand moclonal antibody result in differential effect or development of murine acute and chronic graft-versus-host disease"J.Immunol. 167:9. 4981-4986 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Sakurai, J: "Blockade of CTLA-4 signals inhibits Th2-mediated murine chronic graft-versus-host disease by an enhanced expansion of regulatory"J.Immunol. 164:2. 664-669 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Nozawa, K.Ohata, J Sakurai, J.Hashimoto, H.Miyajima, H.Yagita, H.Okumura, K.and Azuma, M.: "Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differntial effect on development of murine acute and chronic graft-versus-host diseases."J. lmmunol. 167:9. 4981-6 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Sakurai, J.Ohata, J.Saito, K.Miyajima, H.Hirano, T.Kohsaka, T.Enomoto, S.Okumura, K.and Azuma, M.: "Blockade of CTLA-4 signals inhibits Th2-mediated murine chronic graft- versus-host disease by an enhanced expansion of regulatory CD8+ T cells."J. lmmunol. 164:2. 664-9 (2000)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2003-09-17  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi